Main Article Content
Immune thrombocytopenia (ITP) in adults is an acquired chronic immune-mediated disorder defined by isolated thrombocytopenia. In recent years, an improved understanding of the pathophysiology of ITP has been achieved and is now accepted that the disorder is due to increased platelet destruction and decreased platelet production from megakaryocytes. Thrombopoietin (TpO)-receptor agonists (romiplostim and eltrombopag) are new therapeutic modalities in the treatment of ITP. Here we describe a case of an elderly with severe ITP who presented complete remission after short-term use of romiplostim (only 3 weekly doses). This finding is quite interesting as the TpO-receptor agonists are, so far, believed to lead to off-treatment sustained remission very rarely. The common notion of long-term use of romiplostim could be re-examined in future studies. Furthermore, the short term treatment with romiplostim may reduce the cost and the risk of side effects.